Today we are presenting new data from our ALN-AT3 program for the treatment of hemophilia and other bleeding disorders at the 54th
American Society of Hematology (ASH) Annual Meeting in Atlanta. ALN-AT3 comprises part of our “Alnylam 5x15™” strategy, which is aimed at bringing innovative medicines to patients, with a focus on RNAi therapeutics toward genetically defined targets for diseases with very high unmet medical need.
[spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-ASH-AT3posterXpanel-Dec2012-r.pdf" type="(2.3 MB PDF)"] View our poster [/spotlight-link]
[spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734078" type=" "] Read our press release[/spotlight-link]